Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

BioRestorative Therapies, Inc.BRTX · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $4.1M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, late filer, thin datanot computable: distress, fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Mar 26, 2026197 days before the rescan; every figure keyed to the SEC receipt date
Last close$1.922026-10-08; market equity $48.9M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$2$4NovDecJanFebMarAprMayJunJulAugSepOct$1.89
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2012nonen/aQ1
Apr 21, 2022nonen/aQ2
Apr 21, 2025nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 26, 2026; the document on sec.gov.

used in this Annual Report on Form 10-K, or the Annual Report, references to the “Company”, “we”, “us”, were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to “BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100. In March 2022, a United States patent issued in our Disc/Spine Program.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 239.5%[3-4]
Short runway. cash runway is 3.2 months[5]
Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 6 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 44.2
Gross profitability8.2%[1,6]32.2%78.43722025-12-31
Return on invested capitalnot computable9.3%
required facts have no common fiscal period end
Accruals ratio(42.2%)[1,7-9](6.6%)9.98112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five consecutive annual gross margins are required
Solvency, sleeve percentile 90.9
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-03-31
Altman Z double-primenot computable(0.31)
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Net debt to EBITDAnot computable1.82x
required facts have no common fiscal period end
Interest coveragenot computable(4.51x)
latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31
Current ratio0.84x[10-11]2.96x90.98392025-12-31
Growth and financing, sleeve percentile 67.1
Revenue growth, three-year compound44.3%[2,12-14]10.0%15.04152025-12-31
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years(37.2%)[1,9,15-16]2.1%95.67042025-12-31
Net share issuance, one year239.5%[3-4]2.5%90.76342026-03-23

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month179.2%8.0%96hotter than 96 of 100 peers
Distance from 52-week high(58.2%)(31.4%)19closer to its high than 19 of 100 peers
EBIT to enterprise value(34.5%)(1.5%)18pricier than 82 of 100 peers
Free cash flow yield(22.6%)(1.0%)21pricier than 79 of 100 peers
Book value to price0.060.2822pricier than 78 of 100 peers
Sales to price0.010.316pricier than 94 of 100 peers
Composite equity issuance, five yearsnot computable20.3%five-year total-return history is required
Relative strength against the sector, log excess return0.81(0.14)96ahead of 96 of 100 peers

Inputs: market equity $48.2M; EBIT -$15.6M; free cash flow -$10.9M; book equity $3.0M; sales $359,700; debt $250,000; cash $3.1M[17].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(116.0%)✗ fail[7,9]
Operating cash flow above zero-$10.8M✗ fail[8]
Return on assets improved(44.8 pts)✗ fail[7,9,15,18]
Operating cash flow exceeds net income$3.5M✓ pass[7-8]
Long-term leverage felln/a[1,9,15]
Current ratio improved(213.0 pts)✗ fail[10-11,19-20]
No new shares issued239.5%✗ fail[3-4]
Gross margin improved0.4 pts✓ pass[2,6,12,21]
Asset turnover improved(0.3 pts)✗ fail[2,9,12,15]
Cash, filings, liquidity
Cash and equivalents$3.1M[5]
Operating cash flow, four quarters-$11.8M[5,8,22-25]
Months of runway3.2
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing148
10-Q received May 14, 2026
Median daily dollar volume$59,542
63 sessions
Days since newest grade input197

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$4.1M2025-12-312026-03-2610-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$359,7002025-12-312026-03-2610-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding25,478,1702026-03-232026-03-2610-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding7,504,7802025-03-262025-03-2810-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$3.1M2026-03-312026-05-1410-Qfiling · viewer · series
6gross profitus-gaap:GrossProfit$335,8562025-12-312026-03-2610-Kfiling · viewer · series
7net incomeus-gaap:NetIncomeLoss-$14.2M2025-12-312026-03-2610-Kfiling · viewer · series
8operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$10.8M2025-12-312026-03-2610-Kfiling · viewer · series
9assetsus-gaap:Assets$12.3M2024-12-312026-03-2610-Kfiling · viewer · series
10current assetsus-gaap:AssetsCurrent$3.1M2025-12-312026-03-2610-Kfiling · viewer · series
11current liabilitiesus-gaap:LiabilitiesCurrent$3.7M2025-12-312026-03-2610-Kfiling · viewer · series
12revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$401,0002024-12-312026-03-2610-Kfiling · viewer · series
13revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$145,8002023-12-312025-03-2810-Kfiling · viewer · series
14revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$119,8002022-12-312024-06-1110-K/Afiling · viewer · series
15assetsus-gaap:Assets$12.6M2023-12-312025-03-2810-Kfiling · viewer · series
16assetsus-gaap:Assets$16.4M2022-12-312024-06-1110-K/Afiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding25,478,1702026-05-142026-05-1410-Qfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$9.0M2024-12-312026-03-2610-Kfiling · viewer · series
19current assetsus-gaap:AssetsCurrent$11.1M2024-12-312026-03-2610-Kfiling · viewer · series
20current liabilitiesus-gaap:LiabilitiesCurrent$3.7M2024-12-312026-03-2610-Kfiling · viewer · series
21gross profitus-gaap:GrossProfit$372,9282024-12-312026-03-2610-Kfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.8M2026-03-312026-05-1410-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.4M2025-09-302025-11-1210-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.5M2025-06-302025-08-1210-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.8M2025-03-312026-05-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.